GLP-1 receptor agonists gained significant increases in prescriber popularity in 2021, with Semaglutide accounting for 60% of prescriptions by 2023 due to its superior efficacy in clinical trials compared to Liraglutide (22)
This personalization reduces trial-and-error adjustments and gets you to sustainable weight loss faster while protecting your IBS stability
Medical Eligibility Required Semaglutide and Tirzepatide cannot be prescribed to individuals with the following conditions: BMI under 27, eating disorders, Type 1 diabetes, gallbladder disease, substance abuse, recent bariatric surgery (within the past 6 months), pancreatitis or history of recurrent pancreatitis while taking a GLP-1 medication, medullary thyroid cancer, current pregnancy or breastfeeding, plans to become pregnant, diabetic retinopathy, multiple endocrine neoplasia type 2 (MEN2) or family history of MEN2, serious gastrointestinal disorders, or history of allergic reaction to Tirzepatide or Semaglutide
GLP-1 medications may offer meaningful benefits for some people living with MS by: At the same time, its important to be clear: When used thoughtfully, they may be one piece of a broader approach to health alongside MS medications, rehabilitation, nutrition, movement, mental health support, and community
P., Cao G
Hormone Testing: Advanced lab tests will help us identify hormone imbalances such as androgens, estrogen, and progesterone
